In an extension of this initial discovery, we also demonstrated that treating colon cancer cells with subtoxic concentrations of EZH2 inhibitor Taz recapitulates the effects of DCAF1 inhibitor albeit somewhat less efficiently (Supplementary Fig. 20). This evidence concerns the gene EZH2 and colonic neoplasm.